Inflammatory arthritis: biologics may decrease cardiovascular events

Australian study finds association

Patients taking biologics for inflammatory arthritis may have a reduced risk of cardiovascular events (CVE) compared with those who are biologic-naive, but the effect disappears after ceasing the agents, an Australian study suggests.

Analysis of data from 4140 patients in the Australian Rheumatology Association Database (ARAD) showed that those taking anti-TNF biologics had 15% lower risk of a CVE than those who had never taken any biologic drug.

The small number of patients (128) who had taken other types of biologic appeared to be at similar reduced CVE risk, the